Anthony Petrello and the Rise of Nabors

Anthony (Tony) Petrello, is the Chief Executive Officer and President of Nabors Industries Ltd. Nabors is an Standard & Poor 500 oil, natural gas, and geothermal drilling company that employs about 29000 people. Based in Houston, Texas, the company supports a variety of onshore and offshore drilling services generating over $6.2 billion in revenue annually. The company operates more than 50 offshore drilling rigs and 1000 onshore drilling rigs. After surviving post-bankruptcy in the late 1980s, the company began to thrive from 1990 onward. Currently, Nabors is leading the drilling rig market with its innovative rigs designed to withstand much of the wind and wave stress that is seen offshore. Not only this, but Nabors is paving the way with two of the largest and most complex rig in its category.

Anthony Petrello acquired both his Bachelors and Masters degree from Yale University in Mathematics. Following, he went on to get his J.D. from Harvard Law School. This led him to begin his career at the law firm Baker & McKenzie. He held the Managing Partner position from 1986 to 1991, before taking the position of Chief Operating Officer at Nabors Industries in 1991. During this period, the company performed considerably well, despite the recession that the United States was going through at the time. By 1992, he had become the president of the company. Earnings for Nabors continued to grow in the years following, rising rapidly. By the late 1990’s the company was included in the Standard & Poor 500. Despite minor setbacks, the company maintained its dominance in the drilling rig market. In 2011 Petrello began leading the company as the Chief Executive Offer and growth continued. In fact, the stock of the company has risen 180% to date, making Petrello one of the highest paid CEOs in the world.

Learn more: http://people.equilar.com/bio/anthony-petrello-nbr/salary/503049#.WKHy57YrKRs

The Notable Support of Jim Tananbaum in Mindstrong Health’s Innovative Platform

Mindstrong Health announced on patientdaily.com that it had amassed $14 million in a Series A round of funding for supporting its neuropsychiatric treatment and diagnostic platform. ARCH Venture Partners and Foresite Capital led the Series A round. They were later joined by Optum Venture, One Mind Brain Health impact fund, and Berggruen Holdings.

Jim Tananbaum, the acclaimed CEO of Foresite Capital, said that the company’s founding team brought an extensive understanding of the challenges facing the health community care for patients with cognitive health conditions. Furthermore, Dr. Tom Insel, Dr. Paul Dagum, Rick make up the founding team of Mindstrong Health. Jim revealed that a collaboration of the founding team’s collective experience, technical vision, and leadership would help those people who want the benefit from the platform.

The Platform

The Al-powered platform of Mindstrong Health measures brain functions in an objective form through monitoring patterns of interaction on special smartphone devices. Dr. Tom Insel, the current president of Mindstrong, mentioned that he was glad about the company’s platform, which allowed a person to measure his/her cognitive function by patterns of scrolling on a smartphone. He added that the smartphone provided an ultimate solution to end the global mental disorders.

Dr. Paul Dagum, the renowned CEO of Mindstrong Health, said that the platform was significant because it provided an objective measurement of the cognitive function. He added on drewaltizer.com that the platform would help in diagnosing chronic diseases such as heart disease and diabetes. Mindstrong Health cited that the outcomes from the clinical trial through the platform would be released the following month.

Jim Tananbaum

Jim is the founder and current CEO of Foresite Capital, which according to InsiderMonkey.com is worth $1.1 billion in asset under management. He has diverse experience of over 20 years in investment and developing healthcare companies. Before establishing his company, he was the founder and esteemed CEO of Theravance. Jim has led investments like Amerigroup, Jazz Pharmaceutical, and Amira Pharmaceutical.

Jim was a student at Harvard Medical School where he earned his M.D. and an M.B.A from the renowned Harvard Business School. He was also enrolled at Yale University where he got his B.S., and B.S.E.E. Jim has been a respectable member of the advisory boards of Yale Engineering School and Harvard-MIT HST program.

Website: officialjimtananbaum.com